ARCH-backed Paradigm snaps up Flatiron’s clinical research business
The Flatiron acquisition complements a $78m funding round, which will aid Paradigm's efforts to integrate clinical trials into routine care.
The Flatiron acquisition complements a $78m funding round, which will aid Paradigm's efforts to integrate clinical trials into routine care.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
